Published on : May 27, 2015
Canaccord Genuity gave a target of US$160.00 to Alnylam Pharmaceuticals in a research report published for the investors, on Tuesday, 26 May, 2015. The enterprise shows a buy rating on the stock of the bio-pharmaceutical firm, at present.
The stocks of Alnylam Pharmaceuticals were trading up about 1.871% during the mid-day trading held on Tuesday, 26 May, 2015, touching US$127.145. A total of 731,803 shares of the stock of the company traded hands. Alnylam Pharmaceuticals showed a low of US$51.930 and a high of US$132.990. The stock possesses a moving average for 50-day of US$113.5 and a moving average for 200-day US$103.1. The market cap of the company is US$10.71 billion.
Alnylam Pharmaceuticals released its previous earnings data on Thursday, May 7, 2015. The biopharmaceutical firm registered US$0.62 EPS for the previous quarter, defeating the consensus estimation of US$0.66 by a total of US$0.04. The firm had generated revenue of US$18.51 million for the previous quarter, comparing to the consensus estimation of US$15.40 million. Over the same quarter in the past year, the firm posted US$0.39 EPS. The revenue generated by the pharma company for the previous quarter was up about 123.9% on an annual basis. Experts estimate that Alnylam Pharmaceuticals to register US$3.000 EPS for the present financial year.
Various other firms also have recently given their views on ALNY. Market experts at Needham & Co. LLC set a target of US$152.00 on the share of Alnylam Pharma and gave the firm a buy rating in a research study on Friday, May 8, 2015.